Drug-eluting devices maker Intersect ENT hopes to raise as much as $80 million in a newly registered initial public offering, according to SEC documents filed this week.
Intersect ENT registers $80M IPO for sinus implants
Otolaryngology/Ear, Nose & Throat (ENT)
MedInvent looks to breach the blood-brain barrier
By Thomas Lee
There’s a fine line between the nose and the brain. Actually, it’s called the olfactory nerve, which researchers believe can serve as an ideal way to deliver drugs to the central nervous system.
White Bear Lake, Minn.-based start-up MedInvent LLC hopes to ride the strong initial sales of its NasoNeb drug delivery device for sinusitis sufferers to eventually target neurological diseases such as Alzheimer’s and epilepsy.
